Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation

BACKGROUND: Hepatitis B immunoglobulin (HBIG) therapy is available in intravenous (IV) or intra-muscular (IM) formulations. Recently, a subcutaneous (SC) formulation was introduced. This study evaluated changes in quality of life when liver transplant (LT) recipients were switched from IV or IM HBIG...

Descripción completa

Detalles Bibliográficos
Autores principales: Volpes, Riccardo, Burra, Patrizia, Germani, Giacomo, Manini, Matteo Angelo, Caccamo, Lucio, Strignano, Paolo, Rizza, Giorgia, Tamè, Mariarosa, Pinna, Antonio Daniele, Calise, Fulvio, Migliaccio, Carla, Carrai, Paola, De Simone, Paolo, Valentini, Maria Filippa, Lupo, Luigi Giovanni, Cordone, Gabriella, Picciotto, Francesco Paolo, Nicolucci, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149917/
https://www.ncbi.nlm.nih.gov/pubmed/32276633
http://dx.doi.org/10.1186/s12955-020-01349-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149917/
https://www.ncbi.nlm.nih.gov/pubmed/32276633
http://dx.doi.org/10.1186/s12955-020-01349-5

Ejemplares similares